November 26, 2012
Wellesley, Mass. – According to a new technical market research report, GLOBAL MARKETS FOR DIABETES THEREAPEUTICS AND DIAGNOSTICS (HLC029D) from BCC Research (www.bccresearch.com), the global market for diabetes therapeutics and diagnostics was valued at $110 billion in 2011 and should reach nearly $118.7 billion in 2012. Total market value is expected to reach nearly $157 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5.7%
The market for diabetes therapeutics and diagnostics can be broken down into three regions: America, Europe, and Asia.
America is expected to have a value of nearly $43 billion in 2012 and $54 billion in 2017, a CAGR of 4.7%.
As a segment, Europe should total $26.8 billion in 2012 and $35.4 billion in 2017, a CAGR of 5.7%
Asia is expected to total $48.9 billion in 2012 and $67.3 billion in 2017, a CAGR of 6.6%
The current diabetes market includes insulin and insulin-delivery devices, various classes of oral hypoglycemic agents, and different types of instruments and devices used for diagnosis and especially for monitoring the level of diabetic control.
Insulin is a hormone of large molecular size that has traditionally been administered by subcutaneous injection; if taken orally in a conventional tablet or capsule, it is destroyed by gut enzymes. Other hypoglycemic drugs are usually capable of being taken orally but some have inherently short half-lives, necessitating frequent dosage.
This report will help its readers:
This report will be valuable to many industry participants, including the following:
Global Markets for Diabetes Therapeutics and Diagnostics( HLC029D )
Publish Date: Jan 2013
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.